Jay Pepose Biography and Net Worth

Director of Ocuphire Pharma

Dr. Jay Pepose is the Director of Ocuphire Pharma.

How old is Jay Pepose?: Dr. Pepose is currently 69 years old. There are 6 older executives and no younger executives at Ocuphire Pharma. Learn More on Jay Pepose's age.
How do I contact Jay Pepose?: The corporate mailing address for Dr. Pepose and other Ocuphire Pharma executives is 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD, 20850. Ocuphire Pharma can also be reached via phone at (248) 681-9815 and via email at [email protected]. Learn More on Jay Pepose's contact information.
Has Jay Pepose been buying or selling shares of Ocuphire Pharma?: Jay Pepose has not been actively trading shares of Ocuphire Pharma during the last quarter. Most recently, on Monday, December 13th, Jay Pepose bought 8,250 shares of Ocuphire Pharma stock. The stock was acquired at an average cost of $3.65 per share, with a total value of $30,112.50. Learn More on Jay Pepose's trading history.
Who are Ocuphire Pharma's active insiders?: Ocuphire Pharma's insider roster includes James Manuso (Director), and Jay Pepose (Director). Learn More on Ocuphire Pharma's active insiders.
Are insiders buying or selling shares of Ocuphire Pharma?: During the last twelve months, Ocuphire Pharma insiders bought shares 4 times. They purchased a total of 40,500 shares worth more than $80,260.00. The most recent insider tranaction occured on May, 22nd when insider Ashwath Jayagopal bought 3,500 shares worth more than $6,160.00. Insiders at Ocuphire Pharma own 8.7% of the company. Learn More about insider trades at Ocuphire Pharma.
Information on this page was last updated on 5/22/2024.

Jay Pepose Insider Trading History at Ocuphire Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/13/2021	Buy	8,250	$3.65	$30,112.50
9/13/2021	Buy	12,631	$4.75	$59,997.25

Jay Pepose Buying and Selling Activity at Ocuphire Pharma

Ocuphire Pharma Company Overview

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.

Today's Range

Now: N/A

50 Day Range

MA: $1.26

$1.17

$1.46

2 Week Range

Now: N/A

Volume

676,700 shs

Average Volume

171,840 shs

Market Capitalization

$30.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.2

24/7 Automated Profits in Crypto

From Crypto Swap Profits | Ad

>> Secure Your Spot On The Groundbreaking Workshop Here